Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blue light therapy shows promise for vitiligo repigmentation

NCT ID NCT07174024

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compared blue light therapy to targeted narrow band UVB for treating stable non-segmental vitiligo in 30 patients. The goal was to see which treatment better restores skin color. Both are light-based therapies, but blue light may be less harsh on the skin.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blue light emitting diode therapy and narrow band UVB phototherapy
What this could lead to
If blue light works as well as UVB, it could offer a gentler, more convenient option for repigmenting vitiligo patches.
What could go wrong
This is a small, completed Phase 4 trial with only 30 patients, so results may not apply to everyone. Blue light may be less effective or cause side effects like skin sensitivity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

30 people

The number who actually took part.

Started

Jan 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All age group. * Both genders. * Subjects with stable non-segmental vitiligo (≥2 patches) acral or non-acral patches of diameter ≤ 2cm. Exclusion Criteria: * Prior treatment with laser therapies for at least 3 months * Recent exfoliation procedures. * Recent surgical procedures. * Poor skin conditions including keloids. * Hypersensitivity to light ( visible and near-infrared). * Medications that make users more sensitive to light. * Anticoagulant and immunosuppressive treatments. * Gestations or breastfeeding. * A personal or family history of skin cancer. * Unstable vitiligo (older lesions have not progressed for the last 1 years and lack of Koebner phenomena ).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo

Contacts and locations

Locations

  • Cairo University

    Giza, Cairo Governorate, 13114, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.